Maxime Dely: How Do We Balance Benefit and Risk in Chronic Hematologic Diseases?
Maxime Dely, Therapeutic Solutions Sales Consultant at Terumo Blood and Cell Technologies, shared a post on LinkedIn:
“Repeated transfusions: how do we balance benefit and risk in chronic hematologic diseases?
Every year, thousands of patients live thanks to repeated transfusions… but at what long-term cost?
In many chronic hematologic diseases (sickle cell disease, myelodysplastic syndromes, leukemias), red blood cell concentrates are essential to correct anemia
and maintain quality of life.
However, repeated transfusions carry well – documented risks: alloimmunization, making future transfusions more complex, and iron overload, which can lead to hepatic, cardiac, and endocrine complications that are often underestimated.
Iron chelation therapy then becomes necessary, yet burdensome.
Other challenges also arise, such as delayed hemolytic transfusion reactions, sometimes severe, and variability in transfusion thresholds, raising questions about optimal use.
Current guidelines emphasize a more restrictive and individualized approach, tailored to each patient’s condition and disease.
Transfusion is no longer just a supportive act – it is a true therapeutic lever, requiring careful balance between immediate clinical benefit and long-term impact.
Should we more broadly rethink transfusion strategies to better anticipate their chronic consequences?”
More posts featuring Maxime Dely on Hemostasis Today.
-
Jun 23, 2026, 18:27Advancing Gene Therapy Research for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jun 23, 2026, 18:17What Every ITP Patient Wants to Know – ITP Support Association
-
Jun 23, 2026, 18:13Ahsan Fareed: Exploring Heart Failure Readmissions in Iron Deficiency Anemia
-
Jun 23, 2026, 18:09Swarnava Roy: Key Findings on Stress Erythropoiesis and Mitochondrial Retention in RBCs
-
Jun 23, 2026, 17:40Hossam El Benawi: How do We Predict Recurrence Post LVT Resoultion?
-
Jun 23, 2026, 17:39Nicolas Gendron: Do We Really Need All These Hemostasis Tests in Patients on DOACs?
-
Jun 23, 2026, 17:33Maité Mulkers: Time is Brain, and One Reason is That a Thrombus Develops Over Time
-
Jun 23, 2026, 17:32Dhargam Aljebouri: Honoured to Be Part of the Young Professionals Breakfast at ISBT 2026
-
Jun 23, 2026, 17:27Dianne E. van der Wal: Phenotype and Activation of the Endothelium in ET at ISTH 2026